115 related articles for article (PubMed ID: 24337954)
1. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
Santoni M; Santini D; Massari F; Conti A; Iacovelli R; Burattini L; Tortora G; Falconi M; Montironi R; Cascinu S
Cancer Metastasis Rev; 2014 Mar; 33(1):321-31. PubMed ID: 24337954
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
3. Metastatic renal cell carcinoma: many treatment options, one patient.
Rini BI
J Clin Oncol; 2009 Jul; 27(19):3225-34. PubMed ID: 19470934
[TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
5. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
6. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
8. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine for metastatic renal cell carcinoma.
Sonpavde G; Choueiri TK
Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
[TBL] [Abstract][Full Text] [Related]
10. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
Brinkmann OA; Bruns F; Prott FJ; Hertle L
Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
[TBL] [Abstract][Full Text] [Related]
11. Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease.
Phillips JL; Ghadimi BM; Wangsa D; Padilla-Nash H; Worrell R; Hewitt S; Walther M; Linehan WM; Klausner RD; Ried T
Genes Chromosomes Cancer; 2001 May; 31(1):1-9. PubMed ID: 11284029
[TBL] [Abstract][Full Text] [Related]
12. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
13. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
14. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Karam JA; Wood CG
Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in clear cell renal cell carcinoma.
George S; Bukowski RM
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1737-47. PubMed ID: 18062748
[TBL] [Abstract][Full Text] [Related]
16. Gene signatures of progression and metastasis in renal cell cancer.
Jones J; Otu H; Spentzos D; Kolia S; Inan M; Beecken WD; Fellbaum C; Gu X; Joseph M; Pantuck AJ; Jonas D; Libermann TA
Clin Cancer Res; 2005 Aug; 11(16):5730-9. PubMed ID: 16115910
[TBL] [Abstract][Full Text] [Related]
17. [50 years of renal cell carcinoma].
Doehn C
Aktuelle Urol; 2019 Aug; 50(4):378-385. PubMed ID: 31398756
[TBL] [Abstract][Full Text] [Related]
18. Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma.
Massari F; Ciccarese C; Bria E; Porta C; La Russa F; Knuutila S; Artibani W; Porcaro AB; Bimbatti D; Modena A; Sava T; Tortora G; Cheng L; Eccher A; Cima L; Pedron S; Ghimenton C; Martignoni G; Brunelli M
Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):39-43. PubMed ID: 26509904
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapy for Metastatic Renal-Cell Carcinoma.
Choueiri TK; Motzer RJ
N Engl J Med; 2017 Jan; 376(4):354-366. PubMed ID: 28121507
[No Abstract] [Full Text] [Related]
20. Pathology, therapy and prognosis of papillary renal carcinoma.
Fernandes DS; Lopes JM
Future Oncol; 2015; 11(1):121-32. PubMed ID: 25572787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
